Results 41 to 50 of about 1,819,904 (233)

Intelligent Micro/Nanorobots for Targeted Interventional Therapy: From Bench to Clinic

Advanced Robotics Research, EarlyView.
Zirui Zhang et al. reviewed the application and challenges of mobile nanomachines in interventional therapy. By converting exogenous energy, including chemical, magnetic, optical, and ultrasonic sources, into mechanical forces, micro/nanorobots (MNRs) enable precise actuation at unprecedented scales. Evolving far beyond traditional drug delivery, these
Zirui Zhang, Yu Dong, Yongsheng Du, Rui Gao, Lin Zhang, Fei Tong   +5 more
wiley   +1 more source

Drug Eluting Stents en Belgique

, 2007
A côté des« stents » métalliques classiques, il y a, depuis quelques années, aussi des stents spéciaux avec médicament incorporé, pour traiter le rétrécissement des artères coronaires : les « drug eluting stents ». Le médicament est supposé empêcher une nouvelle constriction de l’artère. Quelle est l’efficacité de cette nouvelle technique ? A-t-elle un
Neyt, Mattias, Van Brabandt, Hans, Devriese, Stephan, Mahieu, Joris, De Ridder, Annemieke, De Graeve, Diana, De Laet, Chris   +6 more
openaire   +1 more source

Silk Fibroin for Cardiovascular Medical Devices: Review of Material Properties, Applications, and Clinical Potential

Advanced NanoBiomed Research, EarlyView.
Silk fibroin is an attractive natural biomaterial that can be engineered into diverse cardiovascular constructs, including vascular grafts, cardiac patches, heart valves, and stent coatings. Its tunable biological and mechanical properties have driven substantial preclinical progress; however, widespread clinical translation in cardiovascular ...
Mahsa Haghighattalab, Matt Govendir, Kristina Andelovic, Zachary Och, Fatemeh Karimi, Munira Xaymardan, Tomasz Jungst, Jelena Rnjak‐Kovacina, Nona Farbehi   +8 more
wiley   +1 more source

Decision analytic models, sensitivity analysis and value of information in economic evaluations in health care [PDF]

, 2010
Economic evaluations of health care technologies are now commonly carried out to assess the economic value of new pharmaceuticals, medical devices and procedures.
Bischof, Matthias
core   +1 more source

Efficacy and Safety of Drug-Eluting Stents in the Real World: 8-Year Follow-Up

Arquivos Brasileiros de Cardiologia, 2014
Background: Drug-eluting stents have been used in daily practice since 2002, with the clear advantages of reducing the risk of target vessel revascularization and an impressive reduction in restenosis rate by 50%-70%.
Denise Oliveira Pellegrini, Vitor Osório Gomes, Ricardo Lasevitch, Luis Smidt, Marco Aurélio Azeredo, Priscila Ledur, Rodrigo Bodanese, Leonardo Sinnott, Emílio Moriguchi, Paulo Caramori   +9 more
doaj   +1 more source

The Drug-Eluting Stent Saga [PDF]

Circulation, 2009
Drug-eluting stents (DES) represent a breakthrough technology owing to their potent reduction of restenosis, which is a nuisance in the quality of life of affected patients, a rare cause of myocardial infarction (MI), and the principal shortcoming of stents compared with coronary artery bypass surgery.
Windecker, Stephan, Jüni, Peter
openaire   +2 more sources

Drug‐coated balloons: From conventional designs to next‐generation innovations in vascular therapy

BMEMat, EarlyView.
This review traces the evolution of drug‐coated balloons (DCBs) from conventional designs to next‐generation platforms. We highlight innovations in balloon engineering, coating technologies, and therapeutic agents that enhance localized drug delivery while addressing challenges in efficiency, safety, and biocompatibility for vascular and emerging non ...
Lu Zhang, Jiawei Cui, Jin Wang, Manfred F. Maitz, Rifang Luo, Yunbing Wang   +5 more
wiley   +1 more source

Very Late Stent Thrombosis 42 Months after Implantation of Sirolimus-Eluting Stent and Discontinuation of Antiplatelet Therapy

Case Reports in Medicine, 2009
Although safety profiles of sirolimus-eluting stents do not seem to differ in short-to-medium term from those of bare-metal stents, late stent thrombosis after deployment of drug-eluting stents has emerged as a potential safety concern in the era of high-
Dirk Sibbing, Karl-Ludwig Laugwitz, Lorenz Bott-Flügel, Jürgen Pache   +3 more
doaj   +1 more source

Very Late Pathological Responses to Cobalt–Chromium Everolimus‐Eluting, Stainless Steel Sirolimus‐Eluting, and Cobalt–Chromium Bare Metal Stents in Humans

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017
BackgroundThe “very late” clinical outcomes for durable polymer drug‐eluting stents and bare metal stents (BMSs) have been shown to be dissimilar in clinical studies.
Hiroyoshi Mori, Dheeraj R. Atmakuri, Sho Torii, Ryan Braumann, Samantha Smith, Hiroyuki Jinnouchi, Anuj Gupta, Emanuel Harari, Melsi Shkullaku, Robert Kutys, David Fowler, Maria Romero, Renu Virmani, Aloke V. Finn   +13 more
doaj   +1 more source

Estudo de viabilidade da moldagem por injeção de stents polimericos de PEBD e PCL com fármaco [PDF]

, 2014
Dissertação (mestrado) - Universidade Federal de Santa Catarina, Centro Tecnológico, Programa de Pós-Graduação em Engenharia Mecânica, Florianópolis, 2014.Os stents são implantes médicos que tem evoluído bastante desde os metálicos só ou BRS (Bare metal ...
González García, Andrés Felipe
core